DiviTum™ selected for a new, state of the art, breast cancer study at Karolinska Institutet and University Hospital

Biovicas technology for measuring cell proliferation, DiviTum™, has been selected for inclusion in a new study of women with breast cancer at Karolinska Institutet and Radiumhemmet. The study, PREDIX LumA, aims to include 200 women with hormone-dependent breast cancer that will be treated with endocrine treatment in combination with a new targeted drug (a so [...]

2015-01-27T08:00:04+00:00 January 27th, 2015 08:00|Regulatory|